Cardiac amyloidosis MRI

Cardiac amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiac Amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac amyloidosis MRI On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac amyloidosis MRI All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac amyloidosis MRI
CDC onCardiac amyloidosis MRI
Cardiac amyloidosis MRI in the news
Blogs on Cardiac amyloidosis MRI
Directions to Hospitals Treating Cardiac amyloidosis
Risk calculators and risk factors for Cardiac amyloidosis MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]

Overview

Amyloidosis is an infiltrative disease resulting in deposition of amyloid in the extracellular spaces of the tissues. Amyloid infiltration of the heart leads to expansion of these extracellular spaces resulting in retainment of gadolinium dye during cardiac magnetic resonance imaging. This retainment of gadolinium leads to signal enhancement in the late washout phase during delayed enhanced cardiac imaging.

Cardiac MRI

• Cardiovascular magnetic resonance imaging (CMR) is emerging as a promising tool in the assessment of patients with cardiac amyloidosis (CA).

• Morphological abnormalities, including:
  • Thickening of ventricular and atrial walls and valvular leaflets due to deposition of amyloid fibrils
  • Normal or reduced ventricular sizes
  • Enlarged atria caused by diastolic dysfunction and/or valvular dysfunction due to amyloid deposition

• Functional abnormalities, including:
  • Parameters of diastolic dysfunction characterized by:
    • Abnormal relaxation
    • Restrictive inflow physiology
  • Measures of systolic function (i.e., ejection fraction) are only impaired late in the disease course

• Tissue characterization:
  • Increased intrinsic signal of the myocardium:
    • T1-T2-weighted imaging sequences
    • Late gadolinium enhancement (LGE)
      • The cornerstone technique for the diagnosis of CA.
      • Traditional LGE imaging techniques require an operator-determined null point (i. e., the inversion recovery time at which the normal myocardium appears black or “nulled”).
      • Difficulty nulling the myocardium or myocardial nulling before the blood pool (on TI scout sequence) is strongly suggestive of CA with 100% sensitivity.
      • LGE imaging has become less operator-dependent after the development of a phase-sensitive inversion recovery sequence.
      • LGE is more common in ATTR than AL CA.
      • LGE cannot distinguish between subtypes of CA.
      • A major limitation of LGE is that it is not easily quantifiable.
      • Features of LGE in CA:
        • Global subendocardial enhancement
        • Transmural LGE
        • A focal, patchy LGE (to a lesser degree)
    • T1 mapping (pre- and/or post-contrast)
      • T1 mapping measures the T1 signal of each pixel and/or voxel in an image.
      • Areas of amyloid deposition demonstrate higher native T1 values compared to normal tissues.
      • Native T1 values represent a combined signal from myocyte and extracellular space and can show changes in either or both of these two compartments.
      • Native T1 can be helpful in patients with contraindications to gadolinium.
      • T1 mapping can potentially detect amyloid deposition earlier in the disease course than LGE.
      • Major limitation of native T1 is the lack of reproducibility for various scanners or magnetic field strengths (1.5-T vs. 3.0-T).
      • Post-contrast T1 mapping is performed following gadolinium administration.
    • ECV (expanded extracellular volume) imaging
      • Characterizes the extracellular space
      • Performed following gadolinium administration
      • ECV is more reproducible than absolute T1 values.
      • The ECV values are markedly increased in CA, though cannot distinguish between the subtypes of CA.

• However, CMR might be limited in patients with
  • Atrial fibrillation
  • Severe renal disease (due to contraindications to gadolinium use)
  • Non-compatible intracardiac devices
  • Limited patients’ cooperation to repeatedly hold their breaths

ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance (DO NOT EDIT)

“

CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including Evaluation of dilated cardiomyopathy in the setting of normal coronary arteries Patients with positive cardiac enzymes without obstructive atherosclerosis on angiography Patients suspected of amyloidosis or other infiltrative diseases Hypertrophic cardiomyopathy Arrhythmogenic right ventricular dysplasia Syncope or ventricular arrhythmia

”

Images

MRI showing cardiac amyloidosis (yellow arrow).

MRI showing concentric ventricular remodelling (white arrows) secondary to amyloid deposition.

File:Apical 4chamber CMR-CA.mp4

References

Template:WikiDoc Sources CME Category::Cardiology